Intercept upgraded to Outperform from Market Perform at Leerink Leerink upgraded Intercept to Outperform citing an increased probability of success in NASH following last night's data. The firm raised its price target for shares to $445 from $270 saying it was encouraged by the removal of the prior imbalance in serious adverse events.
Intercept price target lowered to $475 from $693 at Citigroup Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCA’s cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.